These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15842653)

  • 41. [Development of the registry for Philadelphia-negative chronic myeloproliferative neoplasia in Hungary].
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Egyed M
    Orv Hetil; 2016 Jan; 157(3):98-103. PubMed ID: 26750731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Epidemiologic features of Philadelphia-negative chronic myeloproliferative disorders in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period].
    Jakó J; Szerafin L
    Orv Hetil; 2017 Apr; 158(15):572-578. PubMed ID: 28393599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloproliferative diseases.
    Silverstein MN
    Postgrad Med; 1977 Feb; 61(2):206-10. PubMed ID: 556856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders.
    Klippel S; Pahl HL
    Pathol Biol (Paris); 2004 Jun; 52(5):267-74. PubMed ID: 15217712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The management and outcome of 18 pregnancies in women with polycythemia vera.
    Robinson S; Bewley S; Hunt BJ; Radia DH; Harrison CN
    Haematologica; 2005 Nov; 90(11):1477-83. PubMed ID: 16266894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Robinson SE; Harrison CN
    Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J
    Am J Clin Pathol; 2009 Aug; 132(2):261-80. PubMed ID: 19605821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic myelocytic leukemia and the myeloproliferative diseases during the child-bearing years.
    Miller JB
    J Reprod Med; 1976 Oct; 17(4):217-24. PubMed ID: 1068296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Gianelli U; Bossi A; Cortinovis I; Sabattini E; Tripodo C; Boveri E; Moro A; Valli R; Ponzoni M; M Florena A; F Orcioni G; Ascani S; Bonoldi E; Iurlo A; Gugliotta L; Franco V
    Mod Pathol; 2014 Jun; 27(6):814-22. PubMed ID: 24201120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical aspects of myeloproliferative disorders excluding CML].
    Komatsu N
    Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
    [No Abstract]   [Full Text] [Related]  

  • 55. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
    Brière JB
    Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Polycythemia vera and pregnancy: difficulties for diagnosis and treatment].
    Deruelle P; Bouhassoun J; Trillot N; Jude B; Ducloy AS; Subtil D
    Gynecol Obstet Fertil; 2005 May; 33(5):331-7. PubMed ID: 15878688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pregnancy-related thrombocytosis].
    Jønsson V; Bock JE; Mortensen TH; Staun M; Thorsen S
    Ugeskr Laeger; 2002 Aug; 164(34):3946-9. PubMed ID: 12212474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current challenges in the management of essential thrombocythemia.
    Kleman A; Singavi AK; Michaelis LC
    Clin Adv Hematol Oncol; 2017 Oct; 15(10):773-783. PubMed ID: 29040257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.